ArticleInternational journal of molecular sciences2017
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Registry on Hypomethylating Agents in Myeloid Neoplasms, Including Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) and Acute Myeloid Leukemia (AML)
Austrian Myeloid Registry
Department of Hematology, The Second Affiliated Hospital of Kunming Medical University.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review.PloS one · 2021Pooled it
- Trial
- [Clinical analysis of 3 cases of childhood primary pure erythroid leukemia and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Review
- Epidemiology and prognostic factors of acute erythroid leukemia.Translational cancer research · 2026Article
- C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutatedHaematologica · 2026Article
- Prognostic nomograms for predicting overall and cancer-specific survival in acute erythroid leukemia: a SEER-based study.Discover oncology · 2026Article
- Diagnosis and management of rare acute erythroid leukemia with hemophagocytic lymphohistiocytosis: a case report.Frontiers in oncology · 2026Article
- Successful treatment of multi-hit TP53-mutated myelodysplastic syndromes with erythroid predominance using allogeneic stem cell transplantation and ruxolitinib.Annals of hematology · 2025Article
- [Clinical characteristics and prognosis of acute erythroleukemia in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Article
- Acute Erythroid Leukemia: From Molecular Biology to Clinical Outcomes.International journal of molecular sciences · 2024Review
- A Carbon 21 Steroidal Glycoside with Pregnane Skeleton fromPharmaceuticals (Basel, Switzerland) · 2024Article
- Survival after Pure (Acute) Erythroid Leukemia in the United States: A SEER-Based Study.Cancers · 2023Article
- Molecular Landscapes and Models of Acute Erythroleukemia.HemaSphere · 2021Review
- Erythroleukemia: an Update.Current oncology reports · 2021Review
- A C21-steroidal derivative suppresses T-cell lymphoma in mice by inhibiting SIRT3 via SAP18-SIN3.Communications biology · 2020Article
- Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?Leukemia · 2020Review
- American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.Blood advances · 2020Article
- Genomic subtyping and therapeutic targeting of acute erythroleukemia.Nature genetics · 2019Article
- Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts.Haematologica · 2018Review
- Acute Myeloid Leukaemia: New Targets and Therapies.International journal of molecular sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 20 institutions in 8 countries.
Funding
Abstract
Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.